BioSpace News Archive

Helsinn Group (Helsinn), and BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company that focuses on genetic diseases and cancers, today announced an update to their existing strategic collaboration to develop, manufacture and commercialize infigratinib for oncology indications.

Entasis Therapeutics Holdings Inc. today announced full year 2021 financial results and provided a business update.

Salarius Pharmaceuticals, Inc. today announced that the Company will host a conference call and live audio webcast on Thursday, March 10, 2022, at 5:00 p.m. ET, to discuss its corporate and financial results for the three and 12 months ended December 31, 2021.

Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced financial results for the year ended December 31, 2021.

Palatin Technologies, Inc. today announced that it will host a key opinion leader (KOL) webinar on the unmet medical need in treating patients with dry eye disease (DED) on Monday, March 7, 2022 at 10:30 am ET.

CytoImmune Therapeutics, a clinical-stage cell-therapy company developing a novel class of tumor-reactive engineered natural killer cell-based cancer immunotherapies, today announced that the executive management team will participate in the Cowen’s 42nd Annual Health Care Conference.

Innoviva, Inc. (NASDAQ: INVA) (the “Company” or “Innoviva”) today announced the pricing of $225 million aggregate principal amount of the Company’s 2.125% convertible senior notes due 2028 (the “Notes”).

Recursion (NASDAQ: RXRX) today provided updated guidance on clinical trial starts.

Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, announces today that President and Chief Commercial Officer Fady Boctor will present a corporate overview at the Q1 Investor Summit Conference, which is being held virtually on March 8 – 9, 2022.

HiberCell, a clinical-stage biotechnology company developing therapeutics to address therapeutic resistance, cancer relapse and metastasis, announced today an in-person presentation on the clinical applications of the Company’s odetiglucan treatment for patients with metastatic and late-stage cancer at the Keystone Symposia, Myeloid Cells: From Birth to Immunity and Disease taking place March 6-9, 2022 in Banff, AB, Canada.